Nanoform Finland

1.03 EUR

+3.19 %

3,757 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

+3.19 %
+114.30 %
+39.54 %
-11.77 %
+10.83 %
+14.89 %
-51.68 %
-83.82 %
-79.52 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
88.58M EUR
Turnover
273.68K EUR
Revenue
3.55M
EBIT %
-520.56 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I just listened to the Q1 webcast, and here are a few points regarding the nanoformulation of biological compounds that caught my attention in the management’s comments. The production capacity of the biologics line is already about 10 kg per week. Management commented that one thing...
5/19/2026, 9:21 AM
by jerej
20
The company has certainly landed in quite a sweet spot. Partners see the value add of Nanoform’s technology as so significant that they are willing to cover the trial, development, and production costs on Nanoform’s behalf, yet Nanoform’s margins remain absolutely outrageous. Granted...
5/19/2026, 10:41 AM
19
“This is our first exclusivity agreement for the biologics technology for a therapeutic target” → So, we are talking about a biologic, most likely a mAb (monoclonal antibody). This is why I am excited about the news; this is a preliminary external validation of the generalizability...
5/12/2026, 8:04 AM
by Clark kent
15
S.c. biologics has clearly been the most interesting part of the company, which jerej has explained to us many times. However, as an investment at this moment, Nanoform makes me wonder. Potential significant revenues are still further away even regarding this agreement; this will...
5/12/2026, 8:35 AM
by JusaVaan
13
Let me add that I was never incredibly excited about the benefits of nanoenzalutamide (was it that the tablet count was reduced from four to one or something like that?). However, this implies that it involves converting intravenous administration into a subcutaneous injection, which...
5/12/2026, 8:23 AM
by Clark kent
12
I found this to be an encouraging report. It was good to hear that the partners are footing the bill for the additional work and modifications on nanoenzalutamide. A 94% gross margin is pretty outrageous if this operation actually scales commercially .
5/19/2026, 5:59 AM
10
Q1 report is out. Regarding the nanoenzalutamide project, it says: ” On the small molecules side, our nanoenzalutamide program reached an important inflection point during the quarter. Feedback from a European scientific advice meeting confirmed the strong scientific rationale for...
5/19/2026, 5:47 AM
by JusaVaan
9
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.